Altretamine - CAS 645-05-6
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Altretamine
Catalog Number:
645-05-6
CAS Number:
645-05-6
Description:
Altretamine is an anti-neoplastic agent.
Molecular Weight:
210.28
Molecular Formula:
C9H18N6
COA:
Inquire
MSDS:
Inquire
Targets:
DNA Alkylator/Crosslinker
Chemical Structure
CAS 645-05-6 Altretamine

Related DNA Alkylator/Crosslinker Products


CAS 15663-27-1 Cisplatin

Cisplatin
(CAS: 15663-27-1)

Cisplatin induces cytotoxic by interaction with DNA to form DNA adducts which activate several signal transduction pathways, including Erk, p53, p73, and MAPK, ...

CAS 41575-94-4 Carboplatin

Carboplatin
(CAS: 41575-94-4)

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism.

CAS 13010-47-4 Lomustine

Lomustine
(CAS: 13010-47-4)

Lomustine (420 μM) triggers apoptosis through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively.

CAS 299-75-2 Treosulfan

Treosulfan
(CAS: 299-75-2)

Treosulfan is the prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppresive, and antineoplastic activities. Under physiological ...

CAS 55-98-1 Busulfan

Busulfan
(CAS: 55-98-1)

Busulfan is a cell cycle non-specific alkylating antineoplastic agent.

CAS 23261-20-3 VAL-083

VAL-083
(CAS: 23261-20-3)

VAL-083 is a bi-functional alkylating agent; inhibit U251 and SF188 cell growth in monolayer better than TMZ and caused apoptosis.

CAS 129580-63-8 Satraplatin

Satraplatin
(CAS: 129580-63-8)

Satraplatin, also known as JM216, is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who ha...

Cgp 6809
(CAS: 84069-38-5)

Cgp 6809 is a new methylnitrosoureido-sugar derivative. It is active against a broad spectrum of transplantable tumours in mice and rats. But Phase I clinical t...

Altretamine hydrochloride
(CAS: 2975-00-0)

Altretamine hydrochloride, also called as hexamethylmelamine hydrochloride, is an alkylating agent with apparently less toxicity compared to other cytotoxic dru...

CAS 3778-73-2 Ifosfamide

Ifosfamide
(CAS: 3778-73-2)

Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer.

CAS 154-93-8 Carmustine

Carmustine
(CAS: 154-93-8)

Carmustine is  antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA fun...

CAS 61825-94-3 Oxaliplatin

Oxaliplatin
(CAS: 61825-94-3)

Oxaliplatin is a platinum-based antineoplastic agent used in cancer chemotherapy that inhibits DNA synthesis by conforming DNA adducts in cancer cells.

CAS 92118-27-9 Fotemustine

Fotemustine
(CAS: 92118-27-9)

Fotemustine is a chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of gu...

CAS 18883-66-4 Streptozotocin

Streptozotocin
(CAS: 18883-66-4)

Streptozotocin is a glucosamine-nitrosourea derivative, which is a methylating, carcinogenic, antibiotic and diabetes inducing agent. It is commonly used for th...

CAS 50-18-0 Cyclophosphamide

Cyclophosphamide
(CAS: 50-18-0)

Low-dose preferentially deplets Treg cells; An alkylating agent of the nitrogen mustard type with antineoplastic and immunosuppressive activities; Phase I–II

CAS 232931-57-6 SJG-136

SJG-136
(CAS: 232931-57-6)

SJG136 is a pyrrolobenzodiazepine dimer with potential antineoplastic activity. SJG-136 binds to the minor groove of DNA and induces interstrand cross-links bet...

CAS 31645-39-3 Palifosfamide

Palifosfamide
(CAS: 31645-39-3)

Palifosfamide is a synthetic mustard compound with potential antineoplastic activity. An active metabolite of ifosfamide covalently linked to the amino acid lys...

CAS 645-05-6 Altretamine

Altretamine
(CAS: 645-05-6)

Altretamine is an anti-neoplastic agent.

CAS 85622-93-1 Temozolomide

Temozolomide
(CAS: 85622-93-1)

Temozolomide is an oral chemotherapy drug.The therapeutic benefit of temozolomide depends on its ability to alkylate/methylate DNA, which most often occurs at t...

Reference Reading


1.Topotecan: weighing in when there are many options.
Penson RT1, Seiden MV. Oncologist. 2005 Oct;10(9):698-700.
The manuscript by Armstrong et al. in this issue of The Oncologist, reviewing the toxicity and efficacy of full-dose topotecan delivered as second-line therapy in individuals with small cell lung cancer or ovarian cancer, will likely serve as both the most comprehensive and the final review of this active agent delivered at the U.S. Food and Drug Administration-approved dosage and schedule. The review represents large, relative lyhomogeneous patient populations with prior platinum exposure and convincingly describes topotecan as an agent with activity that is comparable with those of all other approved drugs in this setting and a well-defined and relatively circumscribed set of toxicities. While the activity of topotecan in small cell carcinoma provides individuals with the hope for further palliation at the time of tumor recurrence, as discussed by Dr. Markman in this issue, the best use of this agent in the management of recurrent ovarian cancer is far from clear because, in part, of a growing list of approved active agents, most notably liposomal doxorubicin, gemcitabine, and weekly paclitaxel; a return to platinum; or a host of other agents such as vinorelbine, altretamine, irinotecan, docetaxel, etoposide, and others.
2.Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation.
Sun J1, Deng Y, Wang S, Cao J, Gao X, Dong X. Drug Deliv. 2010 Apr;17(3):164-70. doi: 10.3109/10717541003667764.
Liposomes incorporating sodium deoxycholate (NaDC) were prepared by the method of reverse phase evaporation and used for drug delivery by the oral route. Hexamethylmelamine (HMM), an anti-tumor agent, was chosen as a model drug and encapsulated into liposomes incorporating NaDC (NaDC-Lip). Several properties of NaDC-Lip containing HMM (HMM NaDC-Lip), such as particle size, entrapment efficiency, pinacyanol chloride (PIN) spectral characteristics with various molar ratio of NaDC/PC, as well as the vesicle stability measurements with calcein were evaluated. In vivo, the area under the plasma concentration-time curve obtained from the pharmacokinetics study of HMM NaDC-Lip was found to be approximately 9.76- and 1.21-fold higher than that of HMM solution and HMM Lip, respectively, indicating that NaDC-Lip can be used as a potential carrier for oral drug administration.
3.Preparation, characterization, and optimization of altretamine-loaded solid lipid nanoparticles using Box-Behnken design and response surface methodology.
Gidwani B1, Vyas A1. Artif Cells Nanomed Biotechnol. 2016 Mar;44(2):571-80. doi: 10.3109/21691401.2014.971462. Epub 2014 Nov 3.
The objective of the present study was to prepare solid lipid nanoparticles (SLNs) of altretamine (ALT) by the hot homogenization and ultrasonication method. The study was conducted using the Box-Behnken design (BBD), with a 3(3) design and a total of 17 experimental runs, performed in combination with response surface methodology (RSM). The SLNs were evaluated for mean particle size, entrapment efficiency, and drug-loading. The optimized formulation, with a desirability factor of 0.92, was selected and characterized. In vitro release studies showed a biphasic release pattern from the SLNs for up to 24 h. The results of % EE (93.21 ± 1.5), %DL (1.15 ± 0.6), and mean diameter of (100.6 ± 2.1) nm, were very close to the predicted values.
4.Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ1, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. doi: 10.1007/s00280-008-0703-0. Epub 2008 Feb 28.
PURPOSE: Irofulven (MGI 114, NSC 683863) is a semisynthetic derivative of illudin S, a natural product present in the Omphalotus illudins (Jack O'Lantern) mushroom. This novel agent produces DNA damage, that in contrast to other agents, is predominately ignored by the global genome repair pathway of the nucleotide excision repair (NER)(2) system. The aim of this study was to determine the antitumor activity of irofulven when administered in combination with 44 different DNA damaging agents, whose damage is in general detected and repaired by the genome repair pathway.